Understanding how DNA damage affects cancer treatment
Epigenetic mechanisms controlling single-stranded DNA lesion sensitivity and mutagenesis
This study is looking at how certain DNA damage affects cancer treatments and how repairing that damage might lead to new ways to make those treatments work better, especially for patients using therapies like PARP inhibitors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11248962 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which single-stranded DNA lesions (SSLs) impact the effectiveness of cancer therapies. It focuses on how these lesions are repaired in cells and how this process can lead to mutations that contribute to cancer development. By studying a specific histone variant, macroH2A1, and its role in DNA repair, the research aims to uncover new ways to enhance cancer treatment, particularly in combination with existing therapies like PARP inhibitors. Patients may benefit from insights that could lead to more effective cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing treatment for cancers that involve single-stranded DNA lesions, particularly those receiving therapies that induce such lesions.
Not a fit: Patients with cancers not associated with single-stranded DNA lesions or those not undergoing relevant treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that are more effective at targeting tumors and reducing side effects.
How similar studies have performed: Other research has shown promising results in understanding DNA repair mechanisms and their implications for cancer therapy, suggesting that this approach has potential for success.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Oberdoerffer, Philipp — Johns Hopkins University
- Study coordinator: Oberdoerffer, Philipp
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.